EDOXABAN (edoxaban) by Zydus Lifesciences is fxa. Approved for deep vein thrombosis (dvt), pulmonary embolism (pe) following 5 to 10 days of initial therapy with a parenteral anticoagulant () 1, pulmonary embolism (pe) following 5 to 10 days of initial therapy with a parenteral anticoagulant and 8 more indications.
Drug data last refreshed 44m ago
FXa. It does not require antithrombin III for antithrombotic activity. Edoxaban inhibits free FXa, and prothrombinase activity and inhibits thrombin-induced platelet aggregation. Inhibition of FXa in the coagulation cascade reduces thrombin generation and reduces thrombus formation.
Worked on EDOXABAN at Zydus Lifesciences? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism
A Real World Evidence Retrospective Data Collection Study of Edoxaban and Rivaroxaban
Determining the Clinical Relevance of the Interaction Between Enzalutamide and the Opioid Morphine and the DOAC Edoxaban
A Study to Evaluate Effectiveness and Safety of Edoxaban in Patients 80 Years of Age or Older With Nonvalvular Atrial Fibrillation
Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis